Washington D.C. [USA], Mar 14 : Babies born before 32 weeks' gestation can rapidly acquire some adult immune factors after birth, equivalent to that achieved by infants born at term, finds recent research.
The study, led by researchers from King's College London and Homerton University Hospital, has been published in the journal of 'Nature Communications.'
The team followed babies born before 32 weeks' gestation to identify different immune cell populations, the state of these populations, their ability to produce mediators, and how these features changed post-natally.
They found that all the infants' immune profiles progressed in a similar direction as they aged, regardless of the number of weeks of gestation at birth. Babies born at the earliest gestations -- before 28 weeks -- made a greater degree of movement over a similar time period to those born at later gestation. This suggests that preterm and term infants converge in a similar time frame, and immune development in all babies follows a set path after birth.
Dr Deena Gibbons, a lecturer in Immunology in the School of Immunology and Microbial Sciences, said: "These data highlight that the majority of immune development takes place after birth and, as such, even those babies born very prematurely have the ability to develop a normal immune system."
Infection and infection-related complications are significant causes of death following preterm birth. Despite this, there is limited understanding of the development of the immune system in babies born prematurely, and how this development can be influenced by the environment post-birth.
Some preterm babies who went on to develop infection showed reduced CXCL8-producing T cells at birth. This suggests that infants at risk of infection and complications in the first few months of their life could be identified shortly after birth, which may lead to improved outcomes.
There were limited differences driven by sex which suggests that the few identified may play a role in the observations that preterm male infants often experience poorer outcomes.
The findings build on previous findings studying the infant immune system. Dr Gibbons said: "We are continuing to study the role of the CXCL8-producing T cell and how it can be activated to help babies fight infection. We also want to take a closer look at other immune functions that change during infection to help improve outcomes for this vulnerable group."